EXTENSIVE MACULAR ATROPHY WITH PSEUDODRUSEN (EMAP)
Clinical trials for EXTENSIVE MACULAR ATROPHY WITH PSEUDODRUSEN (EMAP) explained in plain language.
Never miss a new study
Get alerted when new EXTENSIVE MACULAR ATROPHY WITH PSEUDODRUSEN (EMAP) trials appear
Sign up with your email to follow new studies for EXTENSIVE MACULAR ATROPHY WITH PSEUDODRUSEN (EMAP), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Could a blood extract save sight? early trial tests PRP for rare eye diseases
Disease control OngoingThis pilot study tests whether injections of platelet-rich plasma (PRP) made from a patient's own blood can help preserve vision in people with retinitis pigmentosa or a related condition called EMAP. Thirty participants receive three injections over four months, and researchers …
Matched conditions: EXTENSIVE MACULAR ATROPHY WITH PSEUDODRUSEN (EMAP)
Phase: PHASE1, PHASE2 • Sponsor: Rubens Camargo Siqueira • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
Can an arthritis drug save sight? small trial tests adalimumab for rare eye diseases
Disease control OngoingThis pilot study tests whether adalimumab, an anti-inflammatory drug, can help preserve vision in people with retinitis pigmentosa or a related condition called EMAP. Thirty participants will receive three injections into the eye over four months. The main goal is to see if the t…
Matched conditions: EXTENSIVE MACULAR ATROPHY WITH PSEUDODRUSEN (EMAP)
Phase: PHASE1, PHASE2 • Sponsor: Centro de Pesquisa Rubens Siqueira • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC